Business Overview: Medline Inc. (NASDAQ: MDLN)

---

Executive Summary

Medline Inc. is the largest provider of medical-surgical products and supply chain solutions in the United States, serving nearly every point of patient care. Founded in 1966 and headquartered in Northfield, Illinois, Medline completed one of the largest IPOs in recent history when it listed on Nasdaq, following decades as a privately/family-controlled operator.

Medline matters because it occupies a structural position few competitors can match: it is simultaneously a manufacturer of roughly a third of the products it sells and the distributor of the rest, bundled into long-term "Prime Vendor" agreements that make it the single point of contact for a hospital's or clinic's entire medical-surgical supply chain. In fiscal 2025 the company generated $28.4 billion in net sales (up 11.5% year-over-year) and $1.16 billion in net income.

---

1. Core Business Model & How They Work

Medline's economics are built on a hybrid manufacturer-distributor model, reinforced by multi-year exclusivity contracts that are unusually hard to dislodge once signed.

[ Manufacturing (Medline Brand, ~1/3 of volume) ] ⟹ [ Global Sourcing Network (600+ partners, ~40 countries) ]
                           │                                              │
                           └──────────────────┬───────────────────────────┘
                                               ▼
                         [ 70 Distribution Facilities (45 in the U.S.) + 2,100+ MedTrans trucks ]
                                               │
                                               ▼
                 [ Prime Vendor Agreements (multi-year, ~98%+ five-year retention) ]
                                               │
                                               ▼
        [ Hospitals, Surgery Centers, Physician Offices, Post-Acute & Long-Term Care Facilities ]

Key Operational Drivers

1. Prime Vendor Consolidation: Customers sign multi-year agreements to route the bulk of their medical-surgical purchasing through Medline rather than juggling dozens of vendors. Medline reports an average greater than 98% retention rate on these agreements over the past five years — an unusually sticky metric for a distribution business.
2. Vertical Manufacturing Control: Owning ~30 manufacturing facilities (24 in North America) producing Class I and II medical devices gives Medline control over cost, quality, and supply continuity that pure distributors (who resell only) cannot replicate.
3. Logistics Density: Next-day delivery to 95% of the U.S. customer base, built on 26 million square feet of U.S. warehouse space using AI and robotics, lets Medline guarantee service levels that are expensive for a smaller player to match.
4. Diversified, Non-Concentrated Supply Base: No single sourcing partner accounts for more than 5% of total spend, insulating the company from any one supplier's disruption.

---

2. Business Segments

Medline organizes its business around two complementary product pools rather than separate profit-and-loss divisions.

┌─────────────────────────────────────────────────────────────────┐
│                           Medline Inc.                           │
├───────────────────────────────┬───────────────────────────────┤
│         Medline Brand          │     Supply Chain Solutions     │
│   (~190,000 proprietary SKUs)  │  (~145,000 third-party SKUs)   │
└───────────────┬────────────────┴────────────────┬────────────────┘
                ▼                                   ▼
  ┌─────────┬─────────┬──────────┐      ┌─────────────────────────┐
  │Front Line│Surgical │Laboratory│      │ Consulting, 3PL,        │
  │  Care    │Solutions│& Diagnos.│      │ outsourced warehousing,  │
  └─────────┴─────────┴──────────┘      │ route planning           │
                                          └─────────────────────────┘

1. Medline Brand (~190,000 products)

Proprietary products manufactured or designed in-house across three categories: Front Line Care (exam gloves, incontinence care, wound care, skin health), Surgical Solutions (surgical packs, gowns, drapes, instruments), and Laboratory & Diagnostics. This is where Medline's manufacturing scale (2,300+ granted patents, 450+ FDA 510(k) clearances) and margin capture are concentrated.

2. Supply Chain Solutions (~145,000 third-party products)

Products sourced from more than 1,300 outside suppliers, bundled with services — consulting, outsourced warehousing, third-party logistics, and delivery-route planning — that let a health system outsource its entire supply chain operation to Medline rather than managing it internally.

---

3. Product Portfolio

---

4. Competitive Landscape

Medline sits at the intersection of two historically separate businesses — manufacturing and distribution — which shapes who it competes with and how.

• Distribution competitors: McKesson, Cardinal Health, Owens & Minor, and Henry Schein all compete for the same Prime Vendor agreements, but Medline notes these rivals generally rely on third-party manufacturers for the products they resell.
• Manufacturing competitors: Other leading medical-surgical product manufacturers, many of which depend on distributors like McKesson or Cardinal Health to reach hospitals — a channel Medline doesn't need for its own branded products.

                      MANUFACTURING ⟷ DISTRIBUTION POSITIONING
┌────────────────────────────────────────────────────────────────────┐
│ High                                                                 │
│  Manufacturing      [MEDLINE]                                       │
│  Depth                 (hybrid manufacturer + distributor)          │
│                                                                      │
│                                          [Pure med-surg manufacturers]│
│                                           (depend on 3rd-party       │
│                                            distribution)             │
│  Low             [McKesson] [Cardinal Health]                       │
│  Manufacturing   [Owens & Minor] [Henry Schein]                     │
│  Depth           (primarily resell manufactured products)           │
└────────────────────────────────────────────────────────────────────┘
      Low Distribution Reach  ─────────────────────▶  High Distribution Reach

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Prime Vendor Switching Friction: A hospital that consolidates purchasing with Medline under a multi-year contract faces a genuinely disruptive, costly process to unwind that relationship — reflected in the ~98%+ retention rate.
• Manufacturing + Distribution Hybrid: Few competitors combine ~30 owned manufacturing facilities with a 70-facility distribution network; this dual structure lets Medline capture margin at two points in the value chain and insulate itself from any single supplier's cost or availability shocks.
• Logistics Scale: Next-day delivery to 95% of U.S. customers via a 2,100+ truck fleet (MedTrans) and AI/robotics-enabled warehousing is expensive infrastructure that a smaller or newer entrant cannot quickly replicate.

Strategic Risks & Vulnerabilities

1. Healthcare Cost and Reimbursement Pressure: Hospital systems and post-acute providers are under constant pressure to cut supply costs, which caps Medline's pricing power even where it is entrenched.
2. Customer Concentration in a Consolidating Industry: As health systems merge, Medline's largest customers gain their own negotiating leverage, which can compress margins even on sticky Prime Vendor contracts.
3. Product Liability and Recall Exposure: As a manufacturer of Class I/II medical devices, Medline bears direct liability risk that pure distributors avoid.
4. Post-IPO Scrutiny and Leverage: As a newly public company, Medline faces fresh public-market scrutiny of its balance sheet and growth trajectory after decades of private ownership, with net income growth (-3.6% in FY2025) already lagging revenue growth (+11.5%).

---

6. Financial Overview

---

7. Summary Conclusion

Medline's moat rests less on any single patent or product and more on the structural inconvenience of leaving it: once a hospital system signs a multi-year Prime Vendor agreement and Medline's trucks, warehousing, and SKUs become embedded in daily operations, replacing that relationship is operationally painful — and the ~98%+ retention rate shows customers rarely try. The company's dual manufacturing-and-distribution model further means it captures economics that pure-play distributors like McKesson or Cardinal Health cannot.

The near-term watch item is margin: net income fell even as revenue grew sharply in its first year as a public company, and sustaining the moat's economics while facing fresh public-market pressure on cost, leverage, and growth expectations will be the key test of whether this scale advantage continues to translate into shareholder value.